Email Page Print Page

Corporate Governance *



BDSI® Code of Ethical Conduct

On March 24, 2003, BDSI®'s Board of Directors adopted the Code of Ethical Conduct for the company's principal executive and financial officers. (revision: April 2014)


BDSI® Disclosure Policy

BioDelivery Sciences International, Inc. is committed to the fair disclosure of information about the company consistent with the Securities and Exchange Commission's Regulation Fair Disclosure ("Regulation FD"). (revision: April 2015)


Audit Committee Charter - Amended July 2014


Nominating and Corporate Governance Committee Charter - Amended April 2016


Compensation Committee Charter - Amended July 2014


Lead Director Charter - Adopted July 26, 2007



* Each of our Board committees reviews its charter for potential updates on an annual basis.  In addition, our Board of Directors review our company's Code of Ethical Conduct for potential updates on an annual basis.

Get the latest details on our products and services.

Top News

BioDelivery Sciences Announces Preferred Formulary Status for BUNAVAIL on Texas Medicaid
BUNAVAIL moved from non-formulary to preferred status

BioDelivery Sciences Announces Additions to its Board of Directors
Timothy C. Tyson joins BDSI's board as an independent member with over 30 years of pharmaceutical experience

BioDelivery Sciences Cites Impressive Number of Physicians Granted Waiver to Increase Patient Limit for Opioid Dependence Treatment Following Recent HHS Rule
SAMHSA Reports 1,665 Clinicians Granted Waivers at the Increased Limit as of This Week

BioDelivery Sciences to Present at the Ladenburg Thalmann 2016 Healthcare Conference

BioDelivery Sciences Announces Three New Managed Care Agreements; Further Enhancing Access to BUNAVAIL
New contracts improve BUNAVAIL formulary status and give BUNAVAIL access to approximately 200,000 additional prescriptions for buprenorphine products for opioid dependence annually